Plasminogen Activator Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Plasminogen Activator Inhibitor The report assesses ...
January 2022
60 pages
Plasminogen Activator Inhibitor-1 (PAI-1) - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Plasminogen Activator Inhibitor-1 (PAI-1) The report ...
January 2022
60 pages
Plasminogen activators - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Plasminogen Activators The report assesses the active Plasminogen ...
January 2022
60 pages
Platelet Derived Growth Factor Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Platelet Derived Growth Factor Inhibitor The report ...
January 2022
60 pages
Polo-Like Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Polo-Like Kinase Inhibitor The report assesses the active Polo-Like ...
January 2022
60 pages
Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Polo-Like Kinase 1 (PLK1 )Inhibitor The report ...
January 2022
60 pages
Potassium Channel Openers - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Potassium Channel Openers The report assesses ...
January 2022
60 pages
PPAR-Beta / Delta Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “PPAR-Beta / Delta Agonist The report assesses the active PPAR-Beta ...
January 2022
60 pages
Progesterone Receptor (PR) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Progesterone Receptor (PR) Antagonist The report ...
January 2022
60 pages
Progesterone Receptor Agonist - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Progesterone Receptor Agonist The report assesses ...
January 2022
90 pages
Prolactin Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Prolactin Receptor Antagonist The report assesses ...
January 2022
60 pages
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor ...
January 2022
60 pages
Prostaglandin Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Prostaglandin Antagonist The report assesses ...
January 2022
60 pages
Protein Kinase C (PKC) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Protein Kinase C (PKC) Inhibitor The report ...
January 2022
60 pages
Protein-Tyrosine Phosphatase (PTP) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Protein-Tyrosine Phosphatase (PTP) Inhibitor The report ...
January 2022
60 pages
Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitor The ...
January 2022
60 pages
Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022
US$ 2,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Purinergic Receptor (Purinoceptor) Antagonist The ...
January 2022
120 pages
Renin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Renin Inhibitor The report assesses the active Renin Inhibitor ...
January 2022
60 pages
RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “RET (Ret Proto-Oncogene) protein Inhibitor The report ...
January 2022
60 pages
Retinoic Acid Receptors (RARs) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Retinoic Acid Receptors (RARs) Agonist The report ...
January 2022
60 pages
Reversible Anticholinesterases - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Reversible Anticholinesterases The report assesses ...
January 2022
90 pages
RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor ...
January 2022
120 pages
RON (Recepteur d'origine Nantais) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “RON (Recepteur d'origine Nantais) Inhibitor The report ...
January 2022
60 pages
Sclerostin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Sclerostin Inhibitor The report assesses ...
January 2022
60 pages
Secretase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Secretase Inhibitor The report assesses ...
January 2022
90 pages
Selectin Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Selectin Inhibitor ...
January 2022
60 pages
Selective COX-2 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Selective COX-2 Inhibitor The report assesses ...
January 2022
60 pages
Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor The ...
January 2022
60 pages
Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Serotonin Reuptake Inhibitor (SRI) The report ...
January 2022
60 pages
Serotonin Transporter Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Serotonin Transporter Inhibitor The report assesses ...
January 2022
60 pages
Sigma Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Sigma Receptor Agonist The report assesses ...
January 2022
60 pages
STAT Inhibitors - Pipeline Insight, 2022
US$ 2,500.00
... , product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Signal Transducer And Activator Of Transcription 3/5 (STAT3/5) Inhibitor The ...
January 2022
150 pages
Sodium Dependent Glucose Transporter 1 (SGLT1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Sodium Dependent Glucose Transporter 1 (SGLT1) Inhibitor The ...
January 2022
60 pages
Somatostatin Receptor Agonist - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Somatostatin Receptor Agonist The report assesses ...
January 2022
60 pages
Sphingosine 1-Phosphate (S1P) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Sphingosine 1-Phosphate (S1P) Inhibitor The report ...
January 2022
60 pages
Sphingosine 1-Phosphate (S1P) Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Sphingosine 1-Phosphate (S1P) Receptor Agonist The ...
January 2022
60 pages
Squalene Epoxidase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Squalene Epoxidase Inhibitor The report assesses ...
January 2022
60 pages
SRC Family Kinases (SFK) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “SRC Family Kinases (SFK) Inhibitor The report ...
January 2022
60 pages
Sterol 14 Alpha-Demethylase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Sterol 14 Alpha-Demethylase Inhibitor The report ...
January 2022
60 pages
Superoxide Dismutase (SOD) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Superoxide Dismutase (SOD) Inhibitor The report ...
January 2022
60 pages
T Cell Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “T Cell Inhibitor The report assesses the active T Cell Inhibitor ...
January 2022
60 pages
Tau Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Tau Inhibitor The report assesses the active Tau Inhibitor pipeline ...
January 2022
60 pages
Telomerase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Telomerase Inhibitor The report assesses ...
January 2022
60 pages
Tetrahydrofolate Dehydrogenase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Tetrahydrofolate Dehydrogenase Inhibitor The report ...
January 2022
60 pages
TGF-Beta Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “TGF-Beta Inhibitor The report assesses the active TGF-Beta ...
January 2022
60 pages
TGF-Beta-1 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “TGF-Beta-1 Inhibitor The report assesses the active TGF-Beta ...
January 2022
60 pages
TGF-Beta-2 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “TGF-Beta-2 Inhibitor The report assesses the active TGF-Beta ...
January 2022
60 pages
Tie-2 modulators - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Tie-2 modulators The report assesses the active Tie-2 modulators ...
January 2022
60 pages
Tie-2 Receptor Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Tie-2 Receptor Inhibitor The report assesses ...
January 2022
60 pages
